Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin-like receptor CD161 (CD161)
- Target
- CD161
- Molecular classification
- C-type lectin-like receptor, Type II transmembrane protein
01
Overview
CD161 is a type II transmembrane C-type lectin-like receptor expressed on various lymphocyte populations, including NK cells and subsets of T cells. It functions as a marker for innate-like T cells and IL-17-producing T helper (Th17) cells. Its interaction with its ligand LLT1 modulates immune responses, particularly inhibiting NK cell cytotoxicity. CD161 is implicated in chronic inflammation, autoimmunity, viral infection, and cancer, making it a potential therapeutic target. However, its complex and sometimes contradictory functions in different immune cell types pose challenges for therapeutic development.
- Other names
- Killer Cell Lectin-Like Receptor Subfamily B, Member 1KLRB1
02
Mechanism of action
Modulation of immune cell activity via LLT1 interaction.
03
Biological functions
Immune response modulationRegulation of NK cell cytotoxicityCytokine production (IL-17, IL-22, IFNγ)Cell signaling
04
Disease associations
AutoimmunityChronic inflammationViral infectionCancer
05
Safety considerations
Potential for immune dysregulation due to broad expression on immune cells.Unclear signaling function in T cells makes targeted therapies challenging.
06
Biomarkers
CD161 expression on T cells as a marker for Th17 cellsCD161 expression on NK cells as a marker for maturation and cytotoxicity
Beyond the preview
Go deeper on C-type lectin-like receptor CD161 (CD161).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-type lectin-like receptor CD161 (CD161).